利福平敏感结核病晚期临床试验的代表性与不良事件报告:一项系统综述
该系统综述纳入40项利福平敏感结核病治疗试验,评估参与者与全球结核病人群特征的代表性及不良事件报告充分性。试验常排除18岁以下、65岁及以上、妊娠或哺乳期、糖尿病及酗酒或吸毒者,且不良事件报告存在重要缺口。
要点
- 40项试验中,25项(62.5%)排除18岁以下者,12项(30.0%)排除65岁及以上者。
- 34项(85.0%)排除妊娠或哺乳期者,12项(30.0%)排除糖尿病者。
- 9项报告糖尿病入组的试验中,糖尿病参与者汇总比例为9%,低于全球16%的估计。
核心结论
- 试验参与者在人口学和临床特征上不能代表全球结核病疫情,限制了试验结果的普遍性。
- 不良事件报告可通过使用患者报告结局、关键结局标准化定义和统一报告方案可接受性指标来改进。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Embase、Cochrane对照试验中心注册库和Cochrane系统综述数据库,检索时间2000年1月1日至2023年12月10日。
- 纳入每臂至少50例参与者且随访至至少完成治疗的试验,共识别7328篇文章,其中40项符合分析条件。
- 该综述前瞻性注册(PROSPERO ID CRD42022373954),无资金支持。
主要发现
- 人口学特征(包括性别)报告于20420例参与者,其中女性6663例(33%),男性13757例(67%)。
- 40项试验中,25项(62.5%)排除18岁以下者,12项(30.0%)排除65岁及以上者,34项(85.0%)排除妊娠或哺乳期者,12项(30.0%)排除糖尿病者,11项(27.5%)排除酗酒、吸毒或两者兼有者。
- 9项报告糖尿病入组的试验中,糖尿病参与者汇总比例为9%,低于全球结核病患者中糖尿病比例的估计值16%。
- 40项试验中,14项(35.0%)报告研究退出,8项(20.0%)报告临时停药,16项(40.0%)报告永久停用指定治疗,11项(27.5%)报告依从性。
关键数值与推荐
- 纳入标准:每臂参与者至少50例,随访至至少完成治疗。
- 排除标准:比较标准药物不同制剂(如固定剂量复合片剂)的研究;主要入组异烟肼耐药或利福平耐药结核病参与者的研究;评估预防结核感染治疗的研究;测试膳食或维生素补充的研究;测试疫苗或其他免疫干预的研究;测试依从性支持或系统相关机制的研究;入组结核病参与者但结核病治疗本身未随机化的研究(如抗逆转录病毒治疗启动时机的试验);试验方案不可获得或非英文发表的试验。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We did a systematic review and meta-analysis of trials of treatment for rifampicin-susceptible tuberculosis to evaluate the representativeness of participants compared with characteristics of the global population of people with tuberculosis, and the adequacy of adverse event reporting. We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews from Jan 1, 2000, to Dec 10, 2023, for trials that had greater than or equal to 50 participants per arm and had follow-up to at least treatment completion. Studies were excluded if they compared different formulations of standard drugs (eg, fixed-dose combination tablets); aimed to primarily enrol participants with isoniazid-resistant or rifampicin-resistant tuberculosis; evaluated treatment to prevent tuberculosis infection; tested dietary or vitamin supplementation; tested vaccines or other immune-based interventions; tested adherence support or system-related mechanisms; or enrolled participants with tuberculosis, but tuberculosis treatment itself was not randomised (ie, trials of the timing of antiretroviral therapy initiation). Trial protocols and trials not available in English were also excluded. The outcomes were inclusion and exclusion criteria, characteristics of participants, and adverse event reporting. This systematic review was prospectively registered (PROSPERO ID CRD42022373954). We identified 7328 articles, of which 40 were eligible for analysis. Demographic characteristics, including sex, were reported for 20 420 participants, of which 6663 (33%) were female and 13 757 (67%) were male. We found that people who were greatly affected by the global tuberculosis pandemic were frequently excluded from participation: of the 40 trials, 25 (62·5%) excluded people younger than 18 years, 12 (30·0%) excluded people aged 65 years or older, 34 (85·0%) excluded pregnant or lactating people, 12 (30·0%) excluded people with diabetes, and 11 (27·5%) excluded people with excessive alcohol use, drug use, or both. In the nine trials that reported enrolment of people with diabetes, the pooled proportion of participants with diabetes (9%) was lower than global estimates for the proportion of people with tuberculosis who have diabetes (16%). There were important gaps in adverse event ascertainment, analysis, and interpretation. Of the 40 trials, a minority reported measures of regimen acceptability: 14 (35·0%) reported study withdrawal, eight (20·0%) reported temporary and 16 (40·0%) reported permanent discontinuation of assigned therapy, and 11 (27·5%) reported adherence. Participants in trials were not representative of the global tuberculosis pandemic in demographic and clinical characteristics, restricting the generalisability of trial outcomes. Adverse event reporting could be improved through the use of patient-reported outcomes, standardised definitions of key outcomes, and uniform reporting of measures of regimen acceptability. There was no funding for this systematic review.
引用
- Burman W, Luczynski P, Horsburgh CR, et al. Representativeness and adverse event reporting in late-phase clinical trials for rifampin-susceptible tuberculosis: a systematic review. Lancet Infect Dis. 2024. PMID: 39612926. doi:10.1016/S1473-3099(24)00597-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。